Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Lowered by Silvant Capital Management LLC

Silvant Capital Management LLC lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 17,676 shares of the biopharmaceutical company’s stock after selling 1,671 shares during the period. Silvant Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $8,060,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after purchasing an additional 31,184 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares during the last quarter. Orbis Allan Gray Ltd grew its stake in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $662,837,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ:ALNY opened at $322.38 on Wednesday. The firm has a 50 day simple moving average of $349.24 and a 200 day simple moving average of $412.24. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The company has a market cap of $42.75 billion, a PE ratio of 188.53 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.65) earnings per share. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on ALNY shares. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. Chardan Capital reduced their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Finally, Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the transaction, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the sale, the executive vice president directly owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 53,923 shares of company stock worth $18,072,087. 1.20% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.